^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    runimotamab (RG6194)

    i
    Other names: RG6194, BTRC4017A, RO7227780
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    HER2 inhibitor, CD3 agonist
    Related drugs:
    Associations

    News

    Trials
    28d
    A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1, N=537, Active, not recruiting, Genentech, Inc. | Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Apr 2024 --> May 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • Actemra IV (tocilizumab) • runimotamab (RG6194)
    5ms
    A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1, N=537, Recruiting, Genentech, Inc. | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • Actemra IV (tocilizumab) • runimotamab (RG6194)
    1year
    Combined investigation of anti-tumor efficacy and liver safety of bispecific T cell engagers in immune-competent high-throughput co-culturing platform (AACR 2023)
    To evaluate our system, we treated 3D spheroid models with runimotamab (HER2xCD3 BiTE) in the presence of peripheral blood mononuclear cells (PBMCs)...In summary, we have developed a human disease relevant, high-throughput platform for the evaluation of novel immunotherapies closely emulating clinical results. Automation-compatible with up to 192 co-culture conditions per plate it represents a powerful tool for clinical candidate development.
    Clinical • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL17A (Interleukin 17A)
    |
    IL2 expression
    |
    runimotamab (RG6194)
    2years
    A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1a/1b, N=521, Recruiting, Genentech, Inc. | Phase classification: P1 --> P1a/1b | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • Actemra IV (tocilizumab) • runimotamab (RG6194)
    5years
    A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1, N=449, Recruiting, Genentech, Inc. | Trial completion date: May 2024 --> Jun 2023 | Trial primary completion date: May 2024 --> Jun 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    runimotamab (RG6194)